A retrospective study to compare the efficacy of intravitreal Ranibizumab and intravitreal Aflibercept in patients with neovascular wet age related macular degeneration(AMD) affected eyes with or without choroidal vascular hyperpermeability (CVH).

Trial Profile

A retrospective study to compare the efficacy of intravitreal Ranibizumab and intravitreal Aflibercept in patients with neovascular wet age related macular degeneration(AMD) affected eyes with or without choroidal vascular hyperpermeability (CVH).

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2015

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top